Two days ago SENS foundation head told a similar story. The publication system is biased toward low hanging fruit and nothing hard and innovative gets promoted. Didn't have time to ask for more information about the subject sadly. But your comment makes me more than curious now.
But yes, bioRxiv would be a good idea!
To answer some of the naysayers: this is definitely not a quack treatment. The CEO is unconventional, to be sure, but the patient always comes first.
Just to address any lingering doubt: I'm a recipient of this implant, so yes: first hand experience, dogfooding, etc.